HE4: really a novel biomarker for ovarian cancer?

Basit Öğe Kaydı
dc.authorid0000-0002-3166-9052en_US
dc.contributor.authorYucel, E.
dc.contributor.authorIlter, E.
dc.contributor.authorAksungar, F. B.
dc.contributor.authorCelik, A.
dc.contributor.authorPeker, B. H.
dc.contributor.authorSerifsoy, E.
dc.contributor.authorBozkurt, S.
dc.date.accessioned2024-07-12T21:46:34Z
dc.date.available2024-07-12T21:46:34Z
dc.date.issued2017en_US
dc.departmentMaltepe Üniversitesien_US
dc.description.abstractOvarian cancer forms 4% of all cancers and approximately 23% of all gynecological cancers in women and is responsible for the 47% of deaths related to cancers of the genital tract of women. Tumor markers are the biochemical substances which can be detected in the presence of tumors. Generally they are either the products of tumoral tissues or secreted from the normal cells which are in the interaction with tumoral ones. The present authors attempted to determine the efficacy of the tumor marker CA-125 and HE4 to differentiate the malign cases from the benign adnexal masses. A total of 76 patients with the appropriate criteria were included in the study. They were divided into three groups; healthy control group (n=31), ones with benign masses (n=23), and ones with malign ovarian masses (n=22). In the study, when the cut-off values were accepted as 55I U/ml for CA-125 and 150 pM for HE4 in differentiation of benign and malign groups, the sensitivity was found as 59.09%, specificity 91.3%, PPV 86.67% and NPV 70% LR = +6.8. This combination gives one false positive result to every five positive cases which were detected as high. With the combination of CA-125 and HE4, the value of sensitivity was found decreased as expected, although the value of the specificity increased.en_US
dc.identifier.doi10.12892/ejgo3312.2017
dc.identifier.endpage64en_US
dc.identifier.issn0392-2936
dc.identifier.issue1en_US
dc.identifier.pmid29767866en_US
dc.identifier.scopus2-s2.0-85014912942en_US
dc.identifier.scopusqualityN/Aen_US
dc.identifier.startpage59en_US
dc.identifier.urihttps://dx.doi.org/10.12892/ejgo3312.2017
dc.identifier.urihttps://hdl.handle.net/20.500.12415/7945
dc.identifier.volume38en_US
dc.identifier.wosWOS:000396648700011en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherI R O G CANADA, INCen_US
dc.relation.ispartofEUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGYen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.snmzKY00852
dc.subjectTumor markersen_US
dc.subjectHE4en_US
dc.subjectCA-125en_US
dc.subjectAdnexal massen_US
dc.subjectOvarian canceren_US
dc.titleHE4: really a novel biomarker for ovarian cancer?en_US
dc.typeArticle
dspace.entity.typePublication

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu